S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
NASDAQ:INVA

Innoviva - INVA Stock Forecast, Price & News

$13.28
+0.10 (+0.76%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.98
$13.42
50-Day Range
$11.61
$13.78
52-Week Range
$11.56
$20.71
Volume
510,942 shs
Average Volume
555,929 shs
Market Capitalization
$926.68 million
P/E Ratio
4.16
Dividend Yield
N/A
Price Target
$14.00

Innoviva MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
5.4% Upside
$14.00 Price Target
Short Interest
Bearish
14.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
-59.37%
From $3.47 to $1.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.15 out of 5 stars

Medical Sector

1018th out of 1,034 stocks

Pharmaceutical Preparations Industry

491st out of 502 stocks

INVA stock logo

About Innoviva (NASDAQ:INVA) Stock

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Stock News Headlines

Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates
Innoviva Completes Acquisition of La Jolla...
See More Headlines
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Company Calendar

Last Earnings
10/27/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/08/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
5
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+5.4%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$265.85 million
Pretax Margin
109.35%

Debt

Sales & Book Value

Annual Sales
$391.87 million
Cash Flow
$4.68 per share
Book Value
$9.19 per share

Miscellaneous

Free Float
69,162,000
Market Cap
$926.68 million
Optionable
Optionable
Beta
0.57

Social Links


Key Executives

  • Mr. Pavel Raifeld C.F.A. (Age 38)
    Chief Exec. Officer
    Comp: $690.81k
  • Ms. Marianne Zhen CPAMs. Marianne Zhen CPA (Age 53)
    Chief Accounting Officer & Sec.
    Comp: $462.18k













INVA Stock - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings
or view top-rated stocks.

What is Innoviva's stock price forecast for 2023?

2 Wall Street analysts have issued 1-year price objectives for Innoviva's shares. Their INVA share price forecasts range from $14.00 to $14.00. On average, they anticipate the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price.
View analysts price targets for INVA
or view top-rated stocks among Wall Street analysts.

How have INVA shares performed in 2022?

Innoviva's stock was trading at $17.25 at the beginning of 2022. Since then, INVA stock has decreased by 23.0% and is now trading at $13.28.
View the best growth stocks for 2022 here
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.43 by $0.47. The biotechnology company earned $97.86 million during the quarter. Innoviva had a net margin of 78.39% and a trailing twelve-month return on equity of 23.89%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.61%), Vanguard Group Inc. (10.04%), Renaissance Technologies LLC (6.12%), Dimensional Fund Advisors LP (4.21%), LSV Asset Management (3.96%) and State Street Corp (3.54%). Insiders that own company stock include George Bickerstaff, Innoviva, Inc, Marianne Zhen and Plc Glaxosmithkline.
View institutional ownership trends
.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $13.28.

How much money does Innoviva make?

Innoviva (NASDAQ:INVA) has a market capitalization of $926.68 million and generates $391.87 million in revenue each year. The biotechnology company earns $265.85 million in net income (profit) each year or $3.19 on an earnings per share basis.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.

This page (NASDAQ:INVA) was last updated on 12/3/2022 by MarketBeat.com Staff